Mesenchymal Stem Cell-Derived Extracellular Vesicles as Therapeutics and as a Drug Delivery Platform
Mesenchymal Stem Cell-Derived Extracellular Vesicles as Therapeutics and as a Drug Delivery Platform
复制标题
DOI：
10.1002/sctm.18-0226
复制
发表时间：
2019-09-01
影响因子：
6
通讯作者：
Choi, Chulhee
中科院分区：
文献类型：
--
作者：
Baek, Gyuhyeon;Choi, Hojun;Choi, Chulhee
间充质干细胞(MSCs)是最容易获得的干细胞之一，可以从各种人体组织中获得。它们在组织修复、抗癌治疗和炎症抑制方面的潜在应用引起了人们的极大兴趣。干细胞疗法最初被用于治疗肌营养不良症，并因其在包括心肌梗死、肾损伤、肝损伤和癌症在内的各种疾病模型中的有效性而被广泛研究。在这篇综述中，我们总结了骨髓间充质干细胞衍生的EVS作为药物传递平台的潜在机制。此外，基于目前发表的数据，我们预测了来自MSCs的EVS运送的货运蛋白具有潜在的治疗作用。这些数据可能支持使用MSC来源的EVS加速这一策略从工作台到床边的治疗策略。干细胞转化医学2019；8：880&886
Mesenchymal stem cells (MSCs) are one of the most easily accessible stem cells that can be obtained from various human tissues. They have raised considerable interests for their potential applications in tissue repair, anti-cancer therapy, and inflammation suppression. Stem cell-based therapy was first used to treat muscular dystrophies and has been studied intensively for its efficacy in various disease models, including myocardial infarction, kidney injuries, liver injuries, and cancers. In this review, we summarized the potential mechanisms underlying MSC-derived EVs therapy as a drug delivery platform. Additionally, based on currently published data, we predicted a potential therapeutic role of cargo proteins shuttled by EVs from MSCs. These data may support the therapeutic strategy of using the MSC-derived EVs to accelerate this strategy from bench to bedside. Stem Cells Translational Medicine 2019;8:880&886